Alla Rudinskaya, MD
Rheumatology · Danbury, CTNPI 1891710612
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 23 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Amgen at 32.9% of the total. Reporting peaked in 2022 at $745 and has fallen 51.9% since, to $358 in 2025.
Across 23 payments — averaging $84.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$640
- AstraZeneca$574
- AbbVie$237
- Aurinia Pharma U.S., Inc.$125
- Radius Health, Inc.$125
- UCB, Inc.$125
- plus $116 from 3 others
Across 45 payments — averaging $1588.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Aurinia Pharma U.S., Inc.$39K
- GSK$17K
- AbbVie$15K
What the payments were for
- Food & beverage$1,943100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 6 | $640 |
| AstraZeneca | 8 | $574 |
| AbbVie | 2 | $237 |
| Aurinia Pharma U.S., Inc. | 1 | $125 |
| Radius Health, Inc. | 1 | $125 |
| UCB, Inc. | 1 | $125 |
| Lilly USA, LLC | 2 | $69 |
| GSK | 1 | $26 |
| Sandoz | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,943 in reported general payments places this provider in the 60th percentile of 118 rheumatology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 39 | $199,114 |
| Cimzia (2 Pack)Certolizumab Pegol | 24 | $135,424 |
| Humira(Cf) PenAdalimumab | 17 | $119,570 |
| Teriparatide | 19 | $76,847 |
| RasuvoMethotrexate/Pf | 17 | $13,948 |
| Hydroxychloroquine Sulfate | 176 | $5,338 |
| Diclofenac Sodium | 17 | $4,102 |
| Celecoxib | 61 | $3,428 |
| MethotrexateMethotrexate Sodium | 127 | $3,391 |
| Cevimeline Hcl | 12 | $2,873 |
| Mycophenolate Mofetil | 14 | $2,509 |
| Prednisone | 165 | $1,975 |
| Risedronate Sodium | 11 | $1,550 |
| Alendronate Sodium | 82 | $1,027 |
| Raloxifene Hcl | 27 | $875 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $640 | $199,11439 claims |
| UCB, Inc.Cimzia (2 Pack) | $125 | $135,42424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 118 rheumatology providers in Connecticut.
Other rheumatology in Danbury
- Kenneth MillerDanbury$873K
- Michael SpiegelDanbury$215K
- Richard RoseffDanbury$84K
- Sana ChaudharyDanbury$1K
- Robert SchoenGuilford$638K
- Bret SohnStamford$447K
- Fotios KoumpourasNorth Haven$314K
- James SeiboldFarmington$300K
- John MagaldiTorrington$157K
- Archana SharmaBristol$98K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.